Alan B. Lancz & Associates, Inc. Amphastar Pharmaceuticals, Inc. Call Options Transaction History
Alan B. Lancz & Associates, Inc.
- $108 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AMPH
# of Institutions
286Shares Held
34.9MCall Options Held
74.3KPut Options Held
22.3K-
Black Rock Inc. New York, NY5.94MShares$233 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.71MShares$106 Million0.0% of portfolio
-
Td Asset Management Inc2.14MShares$83.6 Million0.1% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA1.95MShares$76.2 Million0.22% of portfolio
-
Neuberger Berman Group LLC New York, NY1.62MShares$63.2 Million0.06% of portfolio
About Amphastar Pharmaceuticals, Inc.
- Ticker AMPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 49,015,200
- Market Cap $1.92B
- Description
- Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-count...